Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
PBLA
$1.51
Panbela Therapeutics
($.07)
(4.43%)
PBLA
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus: $0.00
Revenue: N/A
Thursday
Feb 16
4:10 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, November 10, 2022
Panbela Provides Business Update and Reports Q3 2022 Financial Results
What do you expect when PBLA reports earnings?
Beat
Meet
Miss
Where is PBLA's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$1.68
$1.64
$1.57
$1.53
Support
$1.46
$1.42
$1.35
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics Inc., formerly known as Sun BioPharma Inc., is based in MINNEAPOLIS.
Expectations
›
Panbela Therapeutics
